Digital Health, which is where healthcare, technology, data and analytics converge, holds great promise. The World Health Organisation (WHO) believes it has the potential to improve health for everyone – and so do we.

With an increasing focus on precision medicine, patient centricity and preventative care, we need think differently and we need to think digitally when we are designing healthcare solutions for the future. 

As part of our mission to push the boundaries of collaborative research and expose AstraZeneca to more science and technologies, the BioVentureHub is increasingly focused on supporting the digital dimension of the AZ strategy.

More and more life science companies are going digital and digital companies are going life science; and there is often a lack of complementary skills and know-how.

The BioVentureHub has established a collaboration with IBM Sweden whereby small and medium-sized enterprises (SMEs) connected to IBM Sweden or AstraZeneca’s BioVentureHub will be offered access to the other partner’s open innovation platform.

The collaboration aims to stimulate growth of SMEs, support knowledge exchange between the life science and digital technology industries, and strengthen digital health expertise.

“Our exciting collaboration with IBM will provide SMEs and research groups with a unique, non-competitive, collaboration environment that can contribute with both pockets of expertise and foster breakthrough digital health solutions. Besides supporting growth strategies for Swedish SMEs, we also hope the collaboration will help attract international digital health companies to Sweden,” says Magnus Björsne, CEO, AstraZeneca BioVentureHub.